Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3), are members of the TNF and TNFR superfamilies, respectively, with recognised roles in regulating innate and adaptive immune responses; additional existence of a decoy receptor, DcR3, indicates a tightly regulated...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Gut Ročník 74; číslo 4; s. 652 - 668
Hlavní autori:	Bamias, Giorgos, Menghini, Paola, Pizarro, Theresa T, Cominelli, Fabio
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England BMJ Publishing Group Ltd and British Society of Gastroenterology 01.04.2025 BMJ Publishing Group LTD
Predmet:	Amino acids Animals CROHN'S DISEASE CYTOKINES Gene polymorphism Humans Immune response Immunology Inflammation Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - immunology Intestine Kinases Ligands Lymphoid cells Monoclonal antibodies Pathogenesis Proteins Recent advances in basic science Receptors, Tumor Necrosis Factor, Member 25 - antagonists & inhibitors Receptors, Tumor Necrosis Factor, Member 25 - immunology Receptors, Tumor Necrosis Factor, Member 25 - metabolism Receptors, Tumor Necrosis Factor, Member 25 - physiology Signal Transduction Stromal cells Tumor Necrosis Factor Ligand Superfamily Member 15 - antagonists & inhibitors Tumor Necrosis Factor Ligand Superfamily Member 15 - immunology Tumor Necrosis Factor Ligand Superfamily Member 15 - metabolism Tumor Necrosis Factor Ligand Superfamily Member 15 - physiology Tumor necrosis factor receptors Tumor necrosis factor-TNF ULCERATIVE COLITIS ULCERATIVE COLITIS CROHN'S DISEASE CYTOKINES
ISSN:	0017-5749, 1468-3288, 1468-3288
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3), are members of the TNF and TNFR superfamilies, respectively, with recognised roles in regulating innate and adaptive immune responses; additional existence of a decoy receptor, DcR3, indicates a tightly regulated cytokine system. The significance of TL1A:DR3 signalling in the pathogenesis of inflammatory bowel disease (IBD) is supported by several converging lines of evidence.To provide a comprehensive understanding of what is currently known regarding the TL1A/DR3 system in the context of IBD.TL1A and DR3 are expressed by cellular subsets with important roles for the initiation and maintenance of intestinal inflammation, serving as potent universal costimulators of effector immune responses, indicating their participation in the pathogenesis of IBD. Recent evidence also supports a homoeostatic role for TL1A:DR3 via regulation of Tregs and innate lymphoid cells. TL1A and DR3 are also expressed by stromal cells and may contribute to inflammation-induced or inflammation-independent intestinal fibrogenesis. Finally, discovery of genetic polymorphisms with functional consequences may allow for patient stratification, including differential responses to TL1A-targeted therapeutics.TL1A:DR3 signalling plays a central and multifaceted role in the immunological pathways that underlie intestinal inflammation, such as that observed in IBD. Such evidence provides the foundation for developing pharmaceutical approaches targeting this ligand-receptor pair in IBD.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	0017-5749 1468-3288 1468-3288
DOI:	10.1136/gutjnl-2024-332504